Pathstone Family Office’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$41M Buy
336,521
+323,065
+2,401% +$43M 0.31% 50
2023
Q2
$1.9M Buy
13,456
+1,234
+10% +$170K 0.03% 325
2023
Q1
$1.72M Sell
12,222
-14,700
-55% -$2.1M 0.03% 313
2022
Q4
$3.94M Buy
26,922
+2,350
+10% +$338K 0.03% 326
2022
Q3
$3.02M Buy
24,572
+14,427
+142% +$1.9M 0.03% 321
2022
Q2
$1.35M Buy
10,145
+550
+6% +$74.9K 0.03% 281
2022
Q1
$1.31M Sell
9,595
-340
-3% -$47.4K 0.03% 261
2021
Q4
$1.72M Buy
9,935
+268
+3% +$40.8K 0.04% 217
2021
Q3
$1.41M Buy
9,667
+81
+0.8% +$11.9K 0.04% 218
2021
Q2
$1.26M Sell
9,586
-1,052
-10% -$138K 0.04% 221
2021
Q1
$1.36M Buy
10,638
+8,376
+370% +$1.03M 0.05% 167
2020
Q4
$270K Buy
2,262
+2,238
+9,325% +$273K 0.01% 225
2020
Q3
$3K Hold
24
﹤0.01% 681
2020
Q2
$3K Hold
24
﹤0.01% 595
2020
Q1
$2K Buy
+24
New +$2.48K ﹤0.01% 684
2019
Q4
Sell
-24
Closed -$3K 474
2019
Q3
$3K Hold
24
﹤0.01% 553
2019
Q2
$2K Hold
24
﹤0.01% 587
2019
Q1
$2K Sell
24
-1,676
-99% -$145K ﹤0.01% 754
2018
Q4
$142K Buy
+1,700
New +$159K 0.04% 103

Other funds holding DGX

Pathstone Family Office's DGX Position: Q3 2023 in Review

Pathstone Family Office increased its Quest Diagnostics (DGX) stake by 2,401% in Q3 2023, buying an estimated $43M and bringing the position to 336,521 shares worth $41M. The position accounts for 0.31% of the portfolio, ranked #50.

Pathstone Family Office first reported a position in DGX in Q4 2018 and has held it in 19 quarters since. 794 funds tracked by Wall St. Rank hold DGX as of Q3 2023.

  • Pathstone Family Office held 336,521 shares of Quest Diagnostics worth $41M as of Q3 2023.
  • Pathstone Family Office bought 323,065 Quest Diagnostics shares in Q3 2023, an estimated $43M.
  • Quest Diagnostics made up 0.31% of Pathstone Family Office's portfolio in Q3 2023, its #50 holding.
  • Pathstone Family Office first reported a position in Quest Diagnostics in Q4 2018 and has held it in 19 quarters since.
  • 794 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.